Get the Stockscreener App
81.25
1.28%
1.03
After Hours:
81.25
Henry Schein Inc stock is traded at $81.25, with a volume of 1.12M.
It is up +1.28% in the last 24 hours and up +17.16% over the past month.
Henry Schein Inc is a solutions company for healthcare professionals. It offers healthcare equipment, products, and services to office-based dental and medical practitioners, as well as alternative sites of care. The company's reportable segments are: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology. It generates maximum revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting, and other practice services.
See More
Previous Close:
$80.22
Open:
$80.56
24h Volume:
1.12M
Relative Volume:
0.82
Market Cap:
$9.26B
Revenue:
$13.38B
Net Income/Loss:
$418.00M
P/E Ratio:
24.54
EPS:
3.3112
Net Cash Flow:
$391.00M
1W Performance:
+4.91%
1M Performance:
+17.16%
6M Performance:
+6.14%
1Y Performance:
+14.31%
1-Day Range:
$79.61
$82.17
1-Week Range:
$76.88
$82.17
52-Week Range:
$61.95
$89.29
Henry Schein Inc Stock (HSIC) Company Profile
Name
Henry Schein Inc
Sector
Industry
Phone
(631) 843-5500
Address
135 DURYEA RD, MELVILLE, NY
Compare HSIC vs MCK, COR, CAH, AHG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HSIC
Henry Schein Inc
|
81.25 | 9.14B | 13.38B | 418.00M | 391.00M | 3.3112 |
MCK
Mckesson Corp
|
784.05 | 94.62B | 403.43B | 5.10B | 5.41B | 38.47 |
COR
Cencora Inc
|
281.67 | 54.77B | 328.68B | 2.55B | 1.56B | 13.03 |
CAH
Cardinal Health Inc
|
223.85 | 51.80B | 250.74B | 1.55B | 4.39B | 6.5398 |
AHG
Akso Health Group Adr
|
1.34 | 1.17B | 14.85M | -136.07M | 7.25M | -0.4726 |
Henry Schein Inc Stock (HSIC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-26 | Initiated | BTIG Research | Neutral |
| Apr-15-26 | Initiated | Citigroup | Buy |
| Feb-23-26 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Aug-26-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-25-25 | Downgrade | Stifel | Buy → Hold |
| Jul-14-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-14-25 | Initiated | Wells Fargo | Equal Weight |
| Jan-06-25 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-04-24 | Initiated | Mizuho | Neutral |
| Jul-22-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-12-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-10-23 | Upgrade | Stifel | Hold → Buy |
| Aug-08-22 | Upgrade | UBS | Sell → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Neutral |
| Jun-14-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-13-22 | Resumed | Credit Suisse | Outperform |
| Jan-31-22 | Initiated | Morgan Stanley | Underweight |
| Jan-07-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Oct-01-21 | Resumed | Credit Suisse | Neutral |
| Feb-08-21 | Resumed | Piper Sandler | Overweight |
| Jan-04-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-03-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Apr-07-20 | Upgrade | Goldman | Neutral → Buy |
| Apr-02-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-09-20 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jan-02-20 | Upgrade | Evercore ISI | Underperform → In-line |
| Aug-07-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-30-19 | Initiated | Wolfe Research | Underperform |
| May-15-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-18-19 | Initiated | Guggenheim | Buy |
| Jan-17-19 | Initiated | UBS | Sell |
| Jan-03-19 | Downgrade | Evercore ISI | In-line → Underperform |
| Jan-02-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-08-18 | Reiterated | Barrington Research | Outperform |
| Oct-25-18 | Downgrade | Edward Jones | Hold → Sell |
| Oct-19-18 | Resumed | Goldman | Neutral |
| Oct-04-18 | Reiterated | Robert W. Baird | Outperform |
| Aug-07-18 | Reiterated | Stifel | Hold |
| Apr-24-18 | Downgrade | Goldman | Buy → Neutral |
| Apr-04-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
View All
Henry Schein Inc Stock (HSIC) Latest News
Henry Schein Inc. stock rises Thursday, still underperforms market - MarketWatch
Henry Schein, Inc. $HSIC Shares Sold by JPMorgan Chase & Co. - MarketBeat
This Henry Schein Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
120,000 Shares in Henry Schein, Inc. $HSIC Bought by Heartland Advisors Inc. - MarketBeat
Henry Schein (HSIC) Upgraded to Buy with $100 Price Target - GuruFocus
BTIG Upgrades Henry Schein to Buy From Neutral, Price Target is $100 - marketscreener.com
BTIG upgrades Henry Schein stock rating on strong dental growth - Investing.com
BTIG upgrades Henry Schein stock rating on strong dental growth By Investing.com - Investing.com Canada
Henry Schein Inc. stock outperforms competitors despite losses on the day - MarketWatch
Henry Schein stock: Is Wall Street bullish or bearish? - MSN
Henry Schein Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
WINTON GROUP Ltd Has $3.05 Million Stock Position in Henry Schein, Inc. $HSIC - MarketBeat
Henry Schein, Inc. $HSIC Shares Sold by Lyrical Asset Management LP - MarketBeat
Henry Schein, Inc. (HSIC) Stock Analysis: Navigating Growth in Healthcare Distribution with a 12.61% Upside - DirectorsTalk Interviews
Fiduciary Management Inc. WI Decreases Stock Position in Henry Schein, Inc. $HSIC - MarketBeat
Henry Schein, Inc. $HSIC Holdings Lowered by Nuance Investments LLC - MarketBeat
Norges Bank Makes New Investment in Henry Schein, Inc. $HSIC - MarketBeat
Henry Schein Inc. stock outperforms competitors on strong trading day - MarketWatch
Why Is Henry Schein (HSIC) Up 4.6% Since Last Earnings Report? - Yahoo Finance
Henry Schein sees steady dental demand, $125M profit lift by 2026 - MSN
Eurizon Capital SGR S.p.A. Acquires New Holdings in Henry Schein, Inc. $HSIC - MarketBeat
Henry Schein (HSIC) Q1 2026 Earnings Transcript - AOL.com
Henry Schein, Inc. (HSIC) Stock Analysis: Exploring A 13.89% Potential Upside - DirectorsTalk Interviews
How Henry Schein’s New Chairman and Governance Shift At Henry Schein (HSIC) Has Changed Its Investment Story - simplywall.st
Henry Schein Q1 2026 earnings preview - MSN
Henry Schein Assures 2026 Financial Goals Amid Steady Dental Demand - HarianBasis.co
Henry Schein Sees Steady Dental Demand, $125M Profit Lift by 2026 - TradingView
Here's why Henry Schein (HSIC) is a strong momentum stock - MSN
Henry Schein (NASDAQ: HSIC) SVP files Form 3 on share and option holdings - Stock Titan
Here's Why Henry Schein (HSIC) is a Strong Momentum Stock - Yahoo Finance
Is This the Right Time to Keep HSIC Stock in Your Portfolio? - TradingView
Dental giant Henry Schein announces new independent chairman of the board - Dental Tribune US
Henry Schein (HSIC) ex-director corrects date on 50-share stock gift - Stock Titan
Henry Schein stock (US42548G1040): Dental and medical distributor navigates shifting US healthcare d - AD HOC NEWS
Henry Schein, Inc. (HSIC) Stock Analysis: Healthcare Distributor with 17.52% Potential Upside - DirectorsTalk Interviews
Henry Schein highlights dental momentum, $125M savings goal despite medical softness - MSN
Henry Schein Names New Independent Chairman Amid Governance Shift - The Globe and Mail
Henry Schein appoints William Daniel as independent chairman - Investing.com UK
Henry Schein (HSIC) director reports bona fide 50-share stock gift - Stock Titan
Henry Schein Elects William K. “Dan” Daniel as Independent Chairman of the Board, Succeeding Stan Bergman After 44 Years - Minichart
Henry Schein appoints William Daniel as independent chairman By Investing.com - Investing.com South Africa
Henry Schein, Inc. (HSIC) Announces Key Decisions from 2026 Annu - GuruFocus
Here's Why Henry Schein (HSIC) is a Strong Value Stock - Yahoo Finance
Henry Schein Names William K. Daniel as Independent Chairman - Moomoo
Henry Schein Names New Board Chairman - Dentistry Today
Henry Schein announces the election of William K. "Dan" Daniel as independent chairman of the board - marketscreener.com
Dan Daniel becomes Henry Schein (HSIC) independent chair as Bergman retires - Stock Titan
Henry Schein Announces the Election of William K. “Dan” Daniel as Independent Chairman of the Board - Business Wire
Henry Schein Governance Push Meets Discounted Valuation And Mixed Share Performance - Sahm
Henry Schein (HSIC) director Stanley Bergman gifts 1,040 shares - Stock Titan
Henry Schein stock (US42548G1040): Q1 2026 results and outlook update put margins in the spotlight - AD HOC NEWS
Henry Schein Inc Stock (HSIC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.19%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):